PHARMACEUTICAL AEROSOL COMPOSITION OF POLYVALENT ACTION Russian patent published in 2022 - IPC A61K38/55 A61K31/00 A61K31/616 A61K31/7036 A61K35/76 A61K47/10 A61K47/44 A61K9/08 A61P29/00 A61P31/04 A61P31/12 

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to the pharmaceutical industry, namely to an aerosol composition of polyvalent action based on protease inhibitors for devices with aerosol spraying of a non-propellant type. The pharmaceutical aerosol composition of polyvalent action based on protease inhibitors for devices with aerosol spraying of a non-propellant type differs in that it contains a protease inhibitor or combinations thereof selected from a group of aprotinin, leupeptin, serpin, metalloprotease inhibitor, kamostad in a water-containing solution in the range of pH of 4.0-9.0 with a concentration of active substances of 0.001 mkg – 100 mg per ml of the solution, which additionally contains active substances with another mechanism of pharmacological or pathogenetic action or combinations thereof, namely hydrolytic enzymes selected from a group of trypsin, hyaluronidase, chemise, caspase, antiviral substances selected from a group of rimantadine, oseltamivir, ribavirin, favipiravir, antiviral antibodies, antimicrobial substances selected from a group of tobramycin, colistin, gentamicin, tetracycline, anti-inflammatory substances selected from a group of acetylsalicylic acid, interferon, antibodies against cytokines, superoxide dismutase, viruses and subviral components selected from a group of influenza viruses, paramyxoviruses, togaviruses, flaviviruses, picornaviruses, adenoviruses, smallpox vaccine viruses, coronaviruses, herpes virus, at a final concentration of 0.001 mkg – 100 mg per ml of the composition, intended for generation of aerosol with aerosol particle dispersion of 0.1-300 mcm.

EFFECT: above-described composition of polyvalent action prevents active substances from aggregation and denaturation in aerosol spraying.

4 cl, 13 dwg, 13 tbl, 18 ex